Patient Zero and the Pentagon’s Ebola Vaccine
Will arrival of Ebola in America result in mass vaccination?
Kurt Nimmo
Prison Planet.com
October 1, 2014
The first Ebola patient in the United States will lead to calls for the development of a vaccine.
Last week Defense Secretary Chuck Hagel told the Global Health Security Agenda summit the Pentagon has a longstanding research program on infectious disease, including Ebola. Hagel said the Defense Department will now begin clinical trials for a vaccine candidate.
“On Wednesday,” Hagel said, “we received approval to begin safety testing for one [Ebola] vaccine candidate that will be conducted here at the Walter Reed Army Institute of Research.”
The Pentagon is funding an Ebola vaccine under a $140 million project with Tekmira Pharmaceuticals, a Canadian company.
In August an “experimental serum” was administered to Christian aid workers infected in Liberia. The “mysterious treatment” was produced by Mapp Biopharmaceutical Inc., a company based in San Diego, California. Its antibody research is funded by the U.S. Army.
“The most fascinating aspect of the Ebola vaccine manufacturing process is how quickly they have brought it to the trials phase,” writes Dave Mihalovic for Prevent Disease. “It is virtually impossible for vaccine manufacturers to produce and deliver these drugs in the timeline they have proposed. It typically takes several years from the point of initial vaccine development to human clinical trials, a process which the manufacturers claim is being done in weeks and months. The only way it would have been possible was through years of planning and procurement.”
Ebola: Collaboration Between the Pentagon and Pharmaceutical Corporations
The Rest…HERE
